Molecular Management of Multifocal Atrial Tachycardia in Noonan's Syndrome With MEK1/2 Inhibitor Trametinib.

Meisner, Joshua K; Bradley, David J; Russell, Mark W

Meisner, Joshua K; Bradley, David J; Russell, Mark W.

Affiliation

Meisner JK; Division of Pediatric Cardiology, University of Michigan, Ann Arbor.
Bradley DJ; Division of Pediatric Cardiology, University of Michigan, Ann Arbor.
Russell MW; Division of Pediatric Cardiology, University of Michigan, Ann Arbor.

Circ Genom Precis Med ; 14(5): e003327, 2021 10.

Article in En | MEDLINE | ID: mdl-34463117

Subject(s)

MAP Kinase Kinase 1/antagonists & inhibitors; MAP Kinase Kinase 2/antagonists & inhibitors; Noonan Syndrome; Point Mutation; Proto-Oncogene Proteins c-raf/genetics; Pyridones/administration & dosage; Pyrimidinones/administration & dosage; Tachycardia; Female; Humans; Infant, Newborn; MAP Kinase Kinase 1/genetics; MAP Kinase Kinase 2/genetics; Noonan Syndrome/drug therapy; Noonan Syndrome/enzymology; Noonan Syndrome/genetics; Tachycardia/drug therapy; Tachycardia/enzymology; Tachycardia/genetics

Key words

Noonan Syndrome; cardiac arrhythmia; cardiomyopathy, hypertrophic; molecular targeted therapy; raf-1 Kinase

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridones / Pyrimidinones / Tachycardia / Point Mutation / Proto-Oncogene Proteins c-raf / MAP Kinase Kinase 1 / MAP Kinase Kinase 2 / Noonan Syndrome Limits: Female / Humans / Newborn Language: En Journal: Circ Genom Precis Med Year: 2021 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google